Belsomra (Suvorexant) Regulatory Status: What Women in the US, EU, Canada, and UK Need to Know

Why Regulatory Status Matters for Women Seeking Sleep Treatment

Your ability to get suvorexant through a licensed prescriber depends entirely on where you live. A drug approved in one country is not automatically legal to prescribe, dispense, or import in another. For women, this matters because insomnia prevalence is roughly 1.4 times higher in women than in men across the lifespan, with rates spiking sharply during perimenopause and post-menopause, the exact life stages where many women first seek prescription sleep aid.

Suvorexant works through a mechanism that is genuinely different from the benzodiazepines and Z-drugs that have dominated insomnia treatment for decades. Whether you can access it legally depends on decisions made by the FDA, EMA, Health Canada, and MHRA, and those decisions diverged significantly.

What a Regulatory Approval Actually Means

Approval means the agency concluded that the drug's benefits outweigh its risks for a defined population, based on the data submitted. Non-approval does not always mean the drug was found unsafe. In suvorexant's case, the EMA and Health Canada processes reflect concerns about dose calibration and withdrawal data, not a finding that the compound is inherently dangerous.

The Global Patchwork and Its Effect on Access

Women who travel or relocate between countries often discover that their US prescription for Belsomra cannot be filled abroad. Importing a Schedule IV controlled substance from the US for personal use in a country where it has no marketing authorization is illegal in most jurisdictions. This is a practical problem, not a theoretical one, and it disproportionately affects women in perimenopause and post-menopause who have built a stable, effective sleep regimen around suvorexant.

United States: FDA Approval, Schedule, and Dose History

Suvorexant received FDA approval on August 13, 2014, making it the first dual orexin receptor antagonist (DORA) approved anywhere for the treatment of insomnia characterized by difficulty with sleep onset or sleep maintenance.

The FDA's Dose Debate

The approved dose range (5 mg, 10 mg, 15 mg, 20 mg nightly) reflects a lengthy back-and-forth between Merck and the FDA. Merck originally proposed a maximum dose of 40 mg. The FDA's advisory committee voted in favor of approval but recommended a maximum of 20 mg, citing concerns about next-morning impairment, particularly driving performance. Women are at greater pharmacokinetic risk here: suvorexant plasma exposure (AUC) is approximately 17% higher in women than in men at the same oral dose, likely because of differences in body composition and CYP3A4 activity that vary with hormonal status. The FDA label does not mandate a lower starting dose for women, but the higher exposure is explicitly acknowledged.

Schedule IV Classification

Suvorexant is classified as a Schedule IV controlled substance under the Controlled Substances Act, the same schedule as benzodiazepines and Z-drugs such as zolpidem. This scheduling means that US prescriptions cannot be refilled more than five times or after six months without a new prescription, and prescribers must use a DEA registration number. For telehealth prescribers, Schedule IV substances require compliance with Ryan Haight Act provisions, although pandemic-era flexibilities have extended telemedicine prescribing in many states.

Post-Approval US Label Updates

The FDA has updated the Belsomra label multiple times since 2014. A 2019 label revision added a warning about complex sleep behaviors (sleep-walking, sleep-driving) that could result in serious injury or death, a class-wide update affecting all sedative-hypnotics. A 2022 label update clarified next-morning impairment language. Women using suvorexant should note that the complex-sleep-behavior warning applies regardless of mechanism class.

European Union: Why Suvorexant Never Received EMA Authorization

Suvorexant does not have marketing authorization in any EU member state. Merck submitted a Marketing Authorization Application (MAA) to the European Medicines Agency, but the application was withdrawn before the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a final opinion. Withdrawn applications are distinct from refused applications: when a company withdraws, it avoids a formal negative opinion that would be publicly binding across member states.

What the EMA Process Revealed

EMA withdrawal documents cite concerns about the benefit-risk balance at doses the agency considered clinically effective. Regulators were specifically concerned that doses below 20 mg showed modest efficacy in European trial populations, while doses at or above 20 mg raised next-morning residual sedation signals. The EU insomnia treatment field also already included melatonin receptor agonists (ramelteon is not approved in the EU but Circadin, prolonged-release melatonin, is), along with short-term prescribing of benzodiazepines. From the EMA's perspective, the incremental benefit over existing options was not established convincingly at a dose with an acceptable safety profile.

Practical Reality for Women in the EU

Women living in France, Germany, Spain, Italy, the Netherlands, or any other EU member state cannot receive a legal prescription for suvorexant. No EU-licensed prescriber has the authority to prescribe it, and no licensed pharmacy can dispense it. Women who previously used Belsomra in the US and then relocated to the EU have no equivalent DORA option: lemborexant (Dayvigo), the second-generation DORA approved in the US and Japan, has similarly not received EMA authorization as of early 2025.

Canada: Health Canada's Position on Suvorexant

Health Canada has not approved suvorexant. No Notice of Compliance (NOC) has been issued, meaning the drug has no Drug Identification Number (DIN) and cannot be legally prescribed or dispensed through Canadian pharmacies.

Why Canada Diverged from the US

Health Canada and the FDA share considerable data-sharing infrastructure through the International Council for Harmonisation (ICH), and FDA approvals are often followed by Canadian approvals within one to two years. For suvorexant, that follow-on approval never materialized. Merck's submission to Health Canada encountered similar dose-efficacy-safety trade-off questions that slowed the EU process. Canada's Therapeutic Products Directorate has not published a detailed refusal summary in the public domain, which itself reflects a gap in regulatory transparency that disadvantages patients and clinicians trying to understand what the evidence actually showed.

Special Access Program (SAP)

Canadian women with documented refractory insomnia may request suvorexant through Health Canada's Special Access Program, which allows physicians to apply for unapproved drugs in cases where conventional therapies have failed or are unsuitable. SAP access is granted case-by-case and is not a routine prescribing pathway. Approval is not guaranteed, supply depends on the manufacturer's willingness to provide the drug under SAP terms, and the prescriber bears full clinical responsibility.

United Kingdom: MHRA Status Post-Brexit

Suvorexant is not approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The UK's departure from the EU means it operates its own regulatory process, but the MHRA has not received or approved a standalone application for suvorexant as of January 2025. There is no equivalent of the US SAP process widely available in the UK for this drug through NHS channels.

The MHRA's Equivalent Pathway

UK prescribers can, in principle, access unlicensed medicines through the Specials and Imports route, but this is typically reserved for compounded formulations or licensed drugs from other countries requested for an individual patient where no licensed equivalent exists in the UK. It is rarely used for a drug that has never completed a full UK or EU regulatory review, and it requires a named-patient application. For most women in the UK seeking treatment for chronic insomnia, suvorexant is simply not an accessible option through any routine clinical pathway.

How Suvorexant Works: The Orexin System and Why It Matters for Women

Suvorexant is a dual orexin receptor antagonist (DORA). It blocks both the OX1R and OX2R receptors, preventing the wake-promoting neuropeptides orexin-A and orexin-B (also called hypocretin-1 and hypocretin-2) from binding to those receptors. The result is active promotion of sleep by removing the neurochemical drive to stay awake, rather than non-selectively depressing the central nervous system the way benzodiazepines and Z-drugs do.

Why This Mechanism Is Relevant to Women's Sleep Biology

The orexin system interacts with estrogen. Estrogen receptors are expressed in orexin-producing neurons in the lateral hypothalamus, and declining estrogen during perimenopause and post-menopause is associated with increased orexin tone, which may partly explain why menopausal women experience more difficulty maintaining sleep and more early-morning awakening. A drug that directly dampens orexin signaling is therefore mechanistically targeted at one of the neurobiological drivers of menopausal insomnia.

This does not mean suvorexant has been specifically studied or approved for menopausal insomnia as a distinct indication. The FDA label covers adults with insomnia broadly. The mechanistic alignment with female sleep biology is plausible and supported by preclinical data, but large randomized controlled trials restricted to menopausal women have not been published.

The Herring et al. Phase 3 Trial

The registration trial that most directly supported FDA approval was Herring et al., published in Lancet Neurology in 2014. This was a Phase 3, double-blind, placebo-controlled trial involving 1,021 adults with primary insomnia. Suvorexant at 40 mg (and a lower-dose 20 mg formulation) significantly reduced subjective wake time after sleep onset and time to sleep onset compared with placebo. The trial enrolled a meaningful proportion of women (approximately 62% of participants were female), making the dataset somewhat more representative of the primary insomnia population than many earlier sleep trials. Across the trial, suvorexant 20 mg reduced subjective total sleep time by approximately 22 minutes versus placebo at three months, a clinically modest but statistically significant effect. The authors noted that next-day somnolence was the most common adverse event, reported by 7% of patients on the 20 mg dose versus 3% on placebo.

One useful clinical framework for women considering suvorexant versus other options: think in terms of the mechanism of the sleep problem. If your insomnia is driven primarily by an overactive arousal system (difficulty quieting the mind, hypervigilance, delayed sleep onset), an orexin antagonist addresses that arousal signal directly. If your sleep problem is predominantly driven by vasomotor symptoms (night sweats waking you repeatedly), hormone therapy may resolve the insomnia more completely than any hypnotic, including suvorexant. These are not mutually exclusive, and some women in perimenopause need both.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Suvorexant should not be used during pregnancy. This is not a cautionary preference. Animal reproduction studies showed fetal harm at doses above those used clinically, and there are no adequate, well-controlled studies in pregnant women. The FDA classifies suvorexant under the 2015 Pregnancy and Lactation Labeling Rule (PLLR) rather than the older A-B-C-D-X letter system, but the label's narrative makes clear that use in pregnancy is not supported by available data.

Fetal Risk Considerations

In animal studies, suvorexant administered during organogenesis produced dose-related increases in fetal skeletal malformations at exposures approximately 5 times the maximum recommended human dose. No human teratogenicity data exist because no trials enrolled pregnant participants. For women of reproductive age who are not using reliable contraception, this is a meaningful risk signal that should be discussed before starting the drug.

Lactation

Suvorexant is present in rat milk. Human lactation data do not exist. Given the drug's lipophilicity and CNS activity, transfer into human breast milk is biologically plausible. The FDA label advises that the developmental and health benefits of breastfeeding should be considered alongside the potential risk to the infant and the mother's clinical need. In practical terms, most lactation consultants and sleep medicine specialists would advise against suvorexant use during breastfeeding, particularly in the newborn period, given the complete absence of human data.

Contraception Requirements

Suvorexant is not classified as a teratogen requiring mandatory contraception in the way that isotretinoin or valproate are, but its fetal risk profile warrants a clear conversation about pregnancy planning. Women of reproductive age who are prescribed suvorexant should use reliable contraception if pregnancy is not desired. If pregnancy is planned, suvorexant should be tapered and discontinued before conception, with a plan for managing insomnia during pregnancy through cognitive behavioral therapy for insomnia (CBT-I), which is the first-line treatment for insomnia in pregnancy per ACOG guidance.

Who This Drug Is and Is Not Right for, by Life Stage

Reproductive Years (Ages 18-40)

Suvorexant may be appropriate for women in their reproductive years with chronic primary insomnia that has not responded to CBT-I. Prescribers should confirm the patient is not pregnant and is using reliable contraception before initiating. Women with comorbid anxiety-driven insomnia may benefit from the orexin-directed mechanism, which does not carry the same physiological dependence risk as benzodiazepines, though Schedule IV scheduling means there is still a recognized potential for misuse.

Perimenopause (Typically Ages 45-55)

This is the life stage where suvorexant's orexin-directed mechanism has the most biological plausibility for women's sleep complaints. Night sweats and vasomotor symptoms disrupt sleep architecture independently of orexin tone, so hormone therapy and suvorexant may serve different but complementary roles. Women in perimenopause also need to know that sleep-onset insomnia and sleep-maintenance insomnia both increase during this transition, and suvorexant addresses both.

Post-Menopause

Older women are at higher risk of next-morning sedation from any hypnotic. The FDA label notes that the maximum recommended dose is 20 mg, and the prescribing information recommends starting at 10 mg for most patients. For post-menopausal women, particularly those over 65, starting at 5 mg and titrating slowly is reasonable given the increased half-life seen with lower lean body mass and altered CYP3A4 activity. Falls risk with hypnotics in older women is real: sedative-hypnotics are associated with a 50% increased risk of falls in older adults.

Not Appropriate For

Suvorexant is not appropriate for women with narcolepsy (the drug blocks wake-promoting signals that narcolepsy patients already lack), women with severe hepatic impairment (significantly elevated drug exposure), women who are pregnant or actively breastfeeding, or women taking strong CYP3A4 inhibitors such as ketoconazole or ritonavir without close monitoring and dose adjustment.

Alternatives Available in Countries Where Suvorexant Is Not Approved

Women in the EU, Canada, and UK who are told suvorexant is not available face a real clinical gap. These are the most evidence-supported alternatives by jurisdiction:

| Option | EU | Canada | UK | Mechanism | |---|---|---|---|---| | CBT-I (digital or therapist-led) | Available | Available | Available | Behavioral | | Prolonged-release melatonin (Circadin) | Approved over 55 | Available | Licensed | Melatonin agonist | | Eszopiclone (Lunesta) | Not approved | Approved | Not approved | GABA-A positive modulator | | Temazepam | Approved (short-term) | Approved | Licensed | Benzodiazepine | | Trazodone (off-label) | Used off-label | Used off-label | Used off-label | Serotonin antagonist | | Lemborexant | Not approved | Not approved | Not approved | DORA |

CBT-I remains the only intervention with Level I evidence across all life stages and geographies, and it is the treatment that all regulatory agencies and clinical guidelines place above pharmacotherapy as the first step.

PCOS, Thyroid, and Other Female-Specific Conditions: What to Consider

Women with PCOS who have insomnia face a compounding challenge: PCOS is independently associated with higher rates of sleep-disordered breathing and insomnia. Suvorexant is not specifically studied in PCOS, and there is no known direct interaction with metformin or hormonal contraceptives commonly used in PCOS management. CYP3A4 inducers, however, including some anticonvulsants used in PCOS-associated conditions, can significantly reduce suvorexant plasma levels.

Women with hypothyroidism have slower drug metabolism at baseline. Hypothyroidism also independently causes fatigue and sleep disruption, so it is worth optimizing thyroid function (TSH within the reference range, or lower if symptomatic) before attributing insomnia to a primary sleep disorder that requires pharmacotherapy.

Postpartum women should not use suvorexant. The lactation data gap is absolute, and postpartum insomnia, while common, generally responds to behavioral interventions and correction of underlying mood disorders.

If you are a woman in the US with chronic insomnia who has tried CBT-I and needs pharmacotherapy, the current AASM guidelines support suvorexant as an option at 10 mg or 20 mg nightly, with 5 mg as a starting point for women over 65 or anyone at elevated fall risk. Request a next-morning driving-performance conversation with your prescriber before your first dose.